Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
RELATIVITY-127
A Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma
- NCT05912244 ↗
- Active, not recruiting
- Memorial Sloan Kettering Cancer Center
- Focused
We haven't built an HCP commentary report on RELATIVITY-127 (IO102/IO103 and Nivolumab-Relatlimab in Melanoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on RELATIVITY-127 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| YouTube | 3 | |
| Podcasts | 2 | |
| X threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase II Study of IO102/IO103 and Nivolumab-relatlimab Fixed Dose Combination in Untreated, Unresectable Stage III/IV Melanoma
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Melanoma
- Interventions
- IO102/IO103; Nivolumab-Relatlimab
- Arms
- IO102/IO103, Nivolumab, and Relatlimab · Experimental
- Enrollment
- 43
- Primary outcomes
- Overall Response Rate (ORR)
- Sponsor
- Memorial Sloan Kettering Cancer Center with IO Biotech
- Start
- Jun 9, 2023
- Primary completion
- Jun 9, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT05912244 · updated Jun 1, 2026
Publications
linked from the registry- Kjeldsen JW, Lorentzen CL, Martinenaite E, Ellebaek E, Donia M, Holmstroem RB, Klausen TW, Madsen CO, Ahmed SM, Weis-Banke SE, Holmstrom MO, Hendel HW, Ehrnrooth E, Zocca MB, Pedersen AW, Andersen MH, Svane IM. A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma. Nat Med. 2021 Dec;27(12):2212-2223. doi: 10.1038/s41591-021-01544-x. Epub 2021 Dec 9. PubMed 34887574
- Lorentzen CL, Kjeldsen JW, Ehrnrooth E, Andersen MH, Marie Svane I. Long-term follow-up of anti-PD-1 naive patients with metastatic melanoma treated with IDO/PD-L1 targeting peptide vaccine and nivolumab. J Immunother Cancer. 2023 May;11(5):e006755. doi: 10.1136/jitc-2023-006755. PubMed 37217243